Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.
Fiche publication
Date publication
avril 2024
Journal
JAMA network open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MUTTER Catherine
Tous les auteurs :
Gorochov G, Ropers J, Launay O, Dorgham K, da Mata-Jardin O, Lebbah S, Durier C, Bauer R, Radenne A, Desaint C, Vieillard LV, Rekacewicz C, Lachatre M, Parfait B, Batteux F, Hupé P, Ninove L, Lefebvre M, Conrad A, Dussol B, Maakaroun-Vermesse Z, Melica G, Nicolas JF, Verdon R, Kiladjian JJ, Loubet P, Schmidt-Mutter C, Dualé C, Ansart S, Botelho-Nevers E, Lelièvre JD, de Lamballerie X, Kieny MP, Tartour E, Paul S
Lien Pubmed
Résumé
There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response.
Mots clés
Humans, Male, Immunoglobulin G, blood, Female, COVID-19, prevention & control, SARS-CoV-2, immunology, Saliva, immunology, Middle Aged, Adult, Immunoglobulin A, analysis, BNT162 Vaccine, Antibodies, Viral, analysis, 2019-nCoV Vaccine mRNA-1273, COVID-19 Vaccines, immunology, Vaccination, methods, Cohort Studies, Aged, Immunity, Mucosal, immunology, France
Référence
JAMA Netw Open. 2024 04 1;7(4):e248051